SS-31 peptide, also known as elamipretide in clinical development and regulatory contexts, is a small mitochondria-targeted tetrapeptide studied for conditions involving mitochondrial dysfunction, cardiolipin biology, oxidative stress, and impaired cellular energy production 1. This educational article reviews what is known from regulatory sources, clinical trials, animal studies, and cellular research, while separating potential therapeutic uses from unsupported online claims. It is not personal medical advice and does not provide dosing, injection, purchasing, or self-treatment instructions.

  • SS-31 is a mitochondria-targeted peptide discussed in scientific literature under names including SS-31, elamipretide, MTP-131, and Bendavia 1.
  • The main research focus is mitochondrial function, especially the inner mitochondrial membrane, cardiolipin, ATP production, reactive oxygen species, and oxidative stress 2.
  • Human evidence exists but is indication-specific. Clinical trials have evaluated elamipretide in primary mitochondrial myopathy, Barth syndrome, cardiac conditions, and other mitochondrial-related disorders 3.
  • Preclinical evidence is broader than human evidence. Mouse and cellular models suggest effects on mitochondrial respiration, oxidative damage, mitochondrial swelling, and skeletal muscle energetics, but these findings do not prove human benefit 4.
  • Potential benefits should be evidence-graded. Energy, fatigue, skeletal muscle, cardiac, kidney, and ageing-related claims vary from clinical research to early human or preclinical evidence.
  • Safety and side effects depend on the product, indication, and study setting. Clinical trials have monitored adverse events, including administration-site reactions, but long-term safety questions vary by population 3.
  • Dosage information should be read only as study or label context. Study doses should not be interpreted as personal dosing advice, and administration routes in trials are not self-use instructions.

Fast Answer

SS-31 peptide is a mitochondria-targeted tetrapeptide better known in clinical literature as elamipretide. It is studied because mitochondrial dysfunction can affect ATP production, oxidative stress, skeletal muscle, heart, kidney, and inherited mitochondrial disease biology 1, 3. Human trials exist, but evidence strength depends on the condition and endpoint. Safety, dosage, administration, and regulatory status should be interpreted through approved labeling, trial records, and clinician-guided review rather than online peptide claims.

What Is the SS-31 Peptide?

SS-31 is a small synthetic peptide designed to concentrate in mitochondria, the cellular structures that generate much of the body’s ATP through oxidative phosphorylation 1, 2. In medical literature, the same compound is often called elamipretide; earlier development names include MTP-131 and Bendavia 1, 3.

The therapeutic interest comes from its proposed interaction with mitochondrial cardiolipin, a specialized lipid in the inner mitochondrial membrane involved in electron transport chain organization and mitochondrial bioenergetics 2, 5. That mechanism is biologically plausible, but the strength of clinical evidence differs by disease area.

Peptide Classification, Elamipretide, and Tetrapeptide Identity

Elamipretide is classified as a tetrapeptide because it contains four amino acid residues; PubChem lists it as a chemical compound associated with mitochondrial-targeted research 1. It is often described as a mitochondria-targeted peptide or mitochondria-targeted antioxidant peptide because it has been studied for effects on mitochondrial oxidative stress and reactive oxygen species 2, 6.

The term “antioxidant peptide” can be misleading if read too broadly. SS-31 is not simply a general antioxidant supplement; research focuses on mitochondrial membrane interactions, cardiolipin, electron transport, and cell signaling pathways 2.

SS-31, Elamipretide, and Szeto-Schiller Nomenclature

The “SS” in SS-31 refers to Szeto-Schiller peptides, a family of aromatic-cationic peptides originally described in mitochondrial-targeting research 7. Elamipretide is the clinical development name most often used in human trials and regulatory materials 3.

This naming matters because searches for “SS-31 peptide” may return preclinical papers, while searches for “elamipretide” often return human trial records, regulatory information, and clinical publications.

Why Mitochondrial Dysfunction Is Central to the Topic

Mitochondrial dysfunction refers to impaired mitochondrial energy production, redox control, membrane potential, or cellular respiration 8. Because mitochondria influence ATP production, apoptosis, metabolic signaling, and oxidative stress, mitochondrial dysfunction is studied in inherited mitochondrial disease, skeletal muscle fatigue, cardiac disease, kidney injury, ageing, and other conditions 8, 9.

For SS-31, the key question is not whether mitochondria matter. The key question is whether changing mitochondrial membrane biology with treatment with SS-31 improves meaningful human outcomes in a specific condition.

How Does SS-31 Peptide Work in the Mitochondrion?

SS-31 is proposed to act within the mitochondrion by interacting with the inner mitochondrial membrane and cardiolipin-rich structures that support electron transport chain function 2, 5. This proposed action of SS-31 may affect mitochondrial respiration, ATP production, reactive oxygen species generation, and resistance to mitochondrial damage in experimental models 5, 6.

Proposed Action of SS-31 at the Inner Mitochondrial Membrane

The inner mitochondrial membrane houses the electron transport chain and ATP synthase, the enzyme complex that helps produce ATP 8. SS-31 is proposed to localize near this membrane and support mitochondrial structure and bioenergetics through cardiolipin-associated effects 2.

In practical terms, the proposed mechanism is not a classic receptor-binding model. Instead, the targeted peptide SS-31 is studied as a compound that may influence mitochondrial membrane organization, oxidative stress, and cellular respiration 2, 5.

Cardiolipin Binding, Electron Transport, and ATP Production

Cardiolipin is a mitochondrial phospholipid that helps stabilize protein complexes in the electron transport chain 10. Barth syndrome, one of the conditions studied with elamipretide, involves abnormal cardiolipin remodeling due to TAZ gene variants 11.

By interacting with mitochondrial cardiolipin, SS-31 may support more efficient electron transfer and reduce electron leak in experimental systems 2, 5. That could, in theory, support mitochondrial ATP production, but clinical outcomes must be tested directly in humans.

Reactive Oxygen Species, Redox Balance, and Oxidative Stress

Mitochondria naturally generate reactive oxygen species during cellular respiration; excessive mitochondrial ROS can contribute to oxidative damage and stress signaling 8, 9. Preclinical SS-31 studies have examined whether the peptide can reduce mitochondrial oxidative stress, prevent mitochondrial depolarization, and limit mitochondrial swelling in injury models 6.

These findings support mechanistic research, not broad claims that antioxidant SS-31 prevents disease in humans. Redox biology is complex, and lowering oxidative stress markers does not automatically translate into better survival, function, or symptoms.

Mechanism of Action of SS-31 in Mitochondrial Function

The mechanism of action of SS-31 is best described as cardiolipin-associated mitochondrial membrane modulation rather than direct hormone receptor activation. Published studies on SS-31 connect the peptide to mitochondrial respiration, ATP synthase activity, reduced oxidative damage, and preservation of mitochondrial structure in experimental systems 2, 5.

Inner Mitochondrial Membrane Targeting and Mitochondrial Cardiolipin

The inner mitochondrial membrane is central because it maintains the electrochemical gradient used to generate ATP 8. SS-31 may help preserve mitochondrial cardiolipin interactions with respiratory-chain proteins, which may explain reported effects on mitochondrial function in some preclinical models 2.

This is also why elamipretide is different from many peptide therapies that act through cell surface receptors or hormone pathways. Its proposed action is intracellular and mitochondrial.

ATP Synthase, Cellular Respiration, and Mitochondrial ATP

ATP synthase converts mitochondrial membrane potential into adenosine triphosphate, the cell’s primary energy currency 8. Research has examined whether SS-31 improves mitochondrial ATP output by supporting electron transport and limiting oxidative disruption of membrane proteins 5.

The important clinical caveat is that improved mitochondrial ATP in cells or animals does not automatically mean improved fatigue, exercise capacity, or patient outcomes. Human trials must measure symptoms, function, safety, and disease-specific endpoints.

Potential Therapeutic Benefits of SS-31 Peptide

Potential benefits of SS-31 peptide should be grouped by evidence level. Some claims are supported by human trials in specific diseases, some are based on early human or biomarker data, and many online claims remain unsupported.

Mitochondrial Energetics and Cellular Energy Outcomes

The most plausible benefit area is mitochondrial energetics. Preclinical studies suggest SS-31 improves mitochondrial respiration and ATP-related measures in selected models, including muscle and injury systems 4, 5.

In human studies, outcomes are more mixed and condition-specific. Clinical trials in primary mitochondrial myopathy have evaluated walking distance, fatigue, and patient-reported outcomes, but trial results have not supported broad claims that SS-31 restores energy for all people 12, 13.

Oxidative Damage, Inflammation, and Cell Signaling

SS-31 may reduce oxidative damage in preclinical models by lowering mitochondrial reactive oxygen species or preserving membrane function 6. Some studies also connect mitochondrial dysfunction to inflammation and signal transduction, but anti-inflammatory claims for SS-31 should be treated as mechanism-based unless tested clinically 9.

The phrase “protective effects of SS-31” is appropriate for animal or cellular models when the endpoint is clearly described. It should not be converted into a general human disease-prevention claim.

Fatigue, Endurance, and Skeletal Muscle Research

Fatigue and exercise intolerance are relevant because skeletal muscle depends heavily on mitochondrial ATP production 8. Studies in aged mice have reported improvements in mitochondrial energetics and skeletal muscle performance after SS-31 exposure, but translation from aged mice to human endurance or frailty remains uncertain 4.

Human studies in mitochondrial myopathy have evaluated functional endpoints such as walking tests and fatigue measures 12, 13. These data are more relevant than online performance claims, but they still apply only to studied populations.

What Is SS-31 Peptide Used or Studied For?

Elamipretide has been studied in mitochondrial and cardiometabolic contexts, including primary mitochondrial myopathy, Barth syndrome, heart failure, reperfusion injury, kidney-related models, and ageing-related muscle research 3, 4. Use should be separated into approved indications, investigational uses, and preclinical research.

Evidence Area What Has Been Studied Evidence Level What It Can and Cannot Show
Barth syndrome Elamipretide in a rare cardiolipin-related mitochondrial disease context 11, 14 Approved or indication-specific regulatory context may depend on jurisdiction; clinical evidence exists Can inform disease-specific use; cannot justify unrelated wellness claims
Primary mitochondrial myopathy Walking, fatigue, and functional outcomes in adults 12, 13 Clinical / early human Can describe trial results; cannot establish benefit for all fatigue
Cardiac disease Heart failure and ischemia-reperfusion research 15, 16 Clinical and preclinical Can support study discussion; cannot imply routine cardiac treatment
Kidney and ischemic injury Animal and mechanistic models 17 Preclinical Can show mechanisms; cannot prove human kidney benefit
Ageing and muscle energetics Aged mice and skeletal muscle bioenergetics 4 Preclinical Cannot prove longevity, anti-aging, or performance outcomes in humans

Primary Mitochondrial Myopathy and Mitochondrial Disease

Primary mitochondrial myopathy is a group of disorders in which mitochondrial defects impair skeletal muscle function and energy metabolism 18. Elamipretide trials in this area have examined function, fatigue, safety, and patient-reported outcomes 12, 13.

The clinical relevance is narrow: these trials do not mean SS-31 should be used for general tiredness, exercise performance, or wellness without medical diagnosis and regulatory context.

Barth Syndrome and Cardiolipin-Related Research

Barth syndrome is an inherited disorder involving cardiomyopathy, skeletal muscle weakness, neutropenia, growth delay, and abnormal cardiolipin remodeling 11. Elamipretide has been studied in Barth syndrome because its proposed cardiolipin-related mechanism aligns with the disease biology 11, 14.

Regulatory status for Barth syndrome should be checked in current FDA, DailyMed, or regional regulator listings because approval status, labeling, and indication wording can change over time 19.

Heart Failure, Cardiac Stress, and Reperfusion Injury

Cardiac muscle has high mitochondrial energy demand, making mitochondrial dysfunction relevant to heart failure and ischemia-reperfusion injury 9. Elamipretide and Bendavia have been evaluated in cardiac clinical research and reperfusion-related studies, but this does not establish routine treatment for heart failure or acute cardiac events 15, 16.

Cardiac symptoms require licensed medical evaluation. Peptide-related research should not delay evidence-based emergency or heart-failure care.

What Does Human Clinical Trial Evidence Show?

Human clinical trial evidence for elamipretide is real but mixed and highly indication-specific. The strongest conclusions come from trial designs, endpoints, sample sizes, statistical results, and regulatory review, not from mechanism alone 3.

Trial Phases, Endpoints, and Patient Populations

Trials have evaluated elamipretide in primary mitochondrial myopathy, Barth syndrome, heart failure, ophthalmologic mitochondrial disease contexts, and other conditions 3. Common endpoints include exercise function, fatigue, patient-reported outcomes, cardiac measures, biomarkers, adverse events, and tolerability 12, 13.

The patient population matters. A study in a rare mitochondrial disease cannot be generalized to healthy adults seeking energy, longevity, or performance effects.

Where Clinical Evidence Is Stronger or Weaker

Clinical evidence is stronger when a trial is randomized, controlled, adequately powered, and tied to meaningful endpoints. It is weaker when findings come from small open-label studies, secondary endpoints, subgroup analyses, or uncontrolled extensions 20.

For SS-31, mechanism and preclinical data are extensive, but human benefit remains dependent on specific diseases and endpoints. This is why claims about broad mitochondrial health should be cautious.

Safety Findings Reported in Human Studies

Clinical trial records and publications monitor adverse events, tolerability, laboratory findings, and discontinuations 3, 12. Reported safety findings must be interpreted in the context of trial duration, route, formulation, dose, and patient disease status.

A lack of severe safety signals in a trial does not prove that unapproved or compounded products are safe. Manufacturing, sterility, dose accuracy, and medical monitoring are separate safety issues.

What Preclinical Research Says About SS-31

Preclinical research includes mouse, rat, tissue, and cellular models. These studies help explain the effect of SS-31 on mitochondrial dysfunction, but they cannot establish clinical efficacy by themselves.

Mouse Models of Mitochondrial Dysfunction and Aged Mice

Aged mice and other animal models have been used to study mitochondrial energetics, skeletal muscle, cardiac injury, kidney injury, and oxidative stress 4, 17. Mice treated with SS-31 may show improved mitochondrial markers in some models, but animal biology does not always translate to humans.

Terms such as “SS-31 improved” or “SS-31 restores” should be tied to the model and endpoint. For example, “SS-31 improved mitochondrial respiration in aged mice” is not the same as “SS-31 improves human ageing.”

Cellular Models, Mitochondrial Respiration, and ATP

Cellular models have evaluated mitochondrial respiration, mitochondrial ATP production, mitochondrial ROS, membrane potential, and oxidative damage 5, 6. These models can show whether peptide SS-31 attenuates a stress response under controlled conditions.

The limitation is external validity. Cells in a dish do not reproduce whole-body pharmacokinetics, immune response, metabolism, comorbid disease, or long-term adverse events.

Interpreting the Effect of SS-31 in Mouse and Cellular Models

The safest interpretation is that SS-31 has biologically plausible mitochondrial effects in preclinical systems. It is not evidence that SS-31 treatment is appropriate for self-directed use, longevity, muscle growth, or disease prevention.

Evidence Limitations and Unanswered Questions

The evidence base has several gaps: limited disease-specific trial populations, uncertain long-term safety in broader groups, variable endpoints, and incomplete translation from animal models. Unsupported online claims often outpace the clinical literature.

Approved Use Versus Investigational Use

Approved use means a regulator has reviewed a specific product for a specific indication, dose, formulation, labeling, and manufacturing standard. Investigational use means the product is still being studied or is not approved for that indication 21.

For elamipretide, current indication-specific status should be verified through FDA, DailyMed, ClinicalTrials.gov, or local regulators before making clinical assumptions 19, 21.

Clinical Outcomes Versus Biomarker Improvements

A biomarker, such as mitochondrial respiration or ATP production, may help explain mechanism. A clinical outcome, such as walking distance, heart function, hospitalization, fatigue improvement, or survival, determines whether a therapy helps patients in a meaningful way 20.

For SS-31, this distinction is essential. Mitochondrial function with SS-31 may improve in some models, but clinical outcomes require direct evidence.

Side Effects and Adverse Events Reported With SS-31

Side effects reported in elamipretide studies vary by trial, route, dose, and population. Human trial records should be used instead of anecdotal reports when assessing adverse events 3.

Commonly Reported Tolerability Findings

Published and registered trials monitor events such as local administration-site reactions, gastrointestinal symptoms, headache, fatigue, laboratory changes, and serious adverse events, depending on the study protocol 3, 12. Event frequency and causality should be checked in the specific trial or label, not inferred from general peptide discussions.

Injection-Site Reactions and Administration-Related Events

Some elamipretide trials used subcutaneous administration, so injection-site reactions are a relevant safety category in study reporting 13, 14. This article does not provide injection instructions or self-administration guidance.

Administration-related safety also includes sterility, product quality, monitoring, and adverse-event reporting. These factors are especially important when distinguishing approved medicines from unapproved or compounded peptides.

Safety Considerations Before SS-31 Treatment

Safety decisions require diagnosis, indication, medical history, current medications, regulatory status, and product quality review. SS-31 may be discussed in mitochondrial disease contexts, but that does not mean it is suitable for every person with fatigue, cardiac symptoms, kidney disease, or interest in mitochondrial health.

Who May Need Extra Caution?

People with serious cardiac disease, kidney disease, liver disease, mitochondrial disease, immune disorders, complex medication regimens, or prior allergic reactions may need additional clinician review before any investigational or prescription peptide therapy is considered. Clinical trials often use inclusion and exclusion criteria to reduce risk and define who is being studied 3, 20.

Pregnancy, Breastfeeding, Pediatric Use, and Older Adults

Pregnancy, breastfeeding, pediatric use, and older-adult use require special caution because safety data may be limited or indication-specific. Rare disease trials may include pediatric or young adult populations, but findings should not be generalized without reviewing the exact product label or protocol 14, 19.

Contraindications and Drug Interaction Considerations

Contraindications and drug interactions depend on the approved label, trial protocol, route, formulation, and patient population. If a current FDA or DailyMed label exists for a specific elamipretide product, that label is the primary source for formal contraindications, warnings, and interaction language 19.

What Contraindications Are Known or Unclear?

In investigational settings, contraindications are often expressed as trial exclusion criteria rather than formal prescribing contraindications 3. When formal labeling is available, it should be used over online summaries.

Readers should not assume that a lack of publicly obvious contraindications means “safe for everyone.” It often means the evidence base is limited or indication-specific.

Potential Interaction Concerns in Mitochondrial or Cardiac Care

Drug interaction concerns may be especially relevant for people taking cardiac medications, mitochondrial disease therapies, anticoagulants, immunomodulators, or investigational agents. Clinical trial protocols may restrict concomitant medications to reduce confounding and safety risks 3, 15.

A clinician or pharmacist can review whether a peptide therapy overlaps with existing treatment risks, monitoring needs, or disease-specific precautions.

What Dosage Has Been Used in Published Studies?

Dosage information for SS-31 should be interpreted only as study or approved-label context. Study doses should not be interpreted as personal dosing advice.

Study Dose Ranges Without Personal Dosing Advice

Clinical trial records show that elamipretide has been studied using defined protocol doses, routes, and schedules, including subcutaneous regimens in mitochondrial myopathy and Barth syndrome trials 13, 14. Earlier dose-ranging research in adults with primary mitochondrial myopathy evaluated multiple dose levels under clinical supervision 12.

If an approved product label applies, its dosage section should be treated as the authoritative source for that product and indication 19. Online dosing protocols are not substitutes for prescribing information or clinician oversight.

Dose, Duration, and Weeks of SS-31 in Trials

Trial duration matters as much as dose. Some studies examine short-term pharmacodynamic or functional outcomes, while others evaluate longer courses or extension periods 3.

When reading “weeks of SS-31” in a study, note the condition, route, formulation, endpoints, and safety monitoring. A study schedule is not a recommendation for personal use.

What Administration Routes Are Discussed in the Literature?

Administration routes discussed in the literature include subcutaneous administration in several mitochondrial disease trials and intravenous administration in some cardiac or acute-care research contexts 13, 15, 16. Route affects pharmacokinetics, clinical monitoring, adverse events, and study interpretation.

Subcutaneous and Intravenous Routes in Research Context

Subcutaneous SS-31 administration appears in chronic disease trial contexts, while intravenous Bendavia/elamipretide has been studied in acute cardiovascular settings 13, 16. These are medical research contexts, not instructions for home use.

How Administration Route Affects Study Interpretation

Different routes can produce different exposure patterns, onset, monitoring needs, and adverse-event profiles. A result from an intravenous acute-care trial cannot be directly applied to a subcutaneous chronic-use scenario without supporting evidence.

Is SS-31 Peptide FDA-Approved or Investigational?

Regulatory status matters because approved products are reviewed for specific indications, labeling, manufacturing quality, dosage, and safety information 21. Elamipretide status should be checked by product name, indication, country, and date because trial development and regulatory decisions can change 19, 21.

Importantly, “SS-31 peptide” sold or discussed online is not automatically equivalent to an approved elamipretide medicine. Regulatory status, source quality, sterility, formulation, and labeling are central safety issues.

Approval Status, ClinicalTrials.gov, and Regulatory Databases

ClinicalTrials.gov can show whether elamipretide has been studied, but trial registration is not the same as approval 3. FDA and DailyMed resources are better suited for verifying current U.S. labeling, while other countries may use different regulators 19, 21.

Readers should verify the exact formulation and indication rather than relying on generic peptide names, marketing claims, or nonmedical sources.

How SS-31 Compares With Related Peptide Therapies

SS-31 is most appropriately compared with other mitochondrial-targeted therapies by mechanism, evidence level, regulatory status, and studied population. For example, MOTS-c is also discussed online as a mitochondrial peptide, but it has a different biological origin and evidence profile; comparing these compounds requires separate evidence review rather than assuming shared effects.

Compared with many peptide therapies that act through receptors, hormones, or extracellular signaling, SS-31 is discussed for mitochondrial cardiolipin and inner membrane biology 2. That mechanism is distinctive, but it does not make SS-31 “better” or appropriate for general use.

Questions to Discuss With a Clinician About Treatment Options

Readers considering peptide-related medical decisions can use this checklist for a clinician discussion:

  • What diagnosis or symptom is being evaluated?
  • Is elamipretide approved for this indication in the relevant country?
  • Are there approved alternatives with stronger clinical evidence?
  • What human studies apply to this condition?
  • What side effects and monitoring issues are relevant?
  • Are pregnancy, breastfeeding, pediatric age, older age, heart disease, kidney disease, or medication interactions concerns?
  • Is the product an approved medicine, an investigational drug, a compounded product, or an unapproved peptide?
  • How would benefits be measured, and what would count as lack of benefit?

The safest way to interpret SS-31 peptide is through evidence quality, regulatory status, safety data, and clinician-guided decision-making. Strong conclusions require approved labeling or well-designed human studies; weaker claims from mouse, cellular, or online sources should be treated cautiously.

REFERENCES

  1. National Center for Biotechnology Information. PubChem Compound Summary: Elamipretide. PubChem database. Accessed 2026.
  2. PubMed indexed literature. Elamipretide, cardiolipin, and the inner mitochondrial membrane. PubMed database. Accessed 2026.
  3. U.S. National Library of Medicine. ClinicalTrials.gov search: elamipretide. ClinicalTrials.gov database. Accessed 2026.
  4. PubMed indexed literature. SS-31, aged mice, and mitochondrial energetics. PubMed database. Accessed 2026.
  5. PubMed indexed literature. SS-31, cardiolipin, and ATP synthase research. PubMed database. Accessed 2026.
  6. PubMed indexed literature. SS-31, reactive oxygen species, and mitochondrial swelling. PubMed database. Accessed 2026.
  7. PubMed indexed literature. Szeto-Schiller peptides and SS-31 mitochondrial research. PubMed database. Accessed 2026.
  8. National Center for Biotechnology Information. Mitochondria and cellular respiration overview. NCBI Bookshelf. Accessed 2026.
  9. PubMed indexed literature. Mitochondrial dysfunction in human disease review literature. PubMed database. Accessed 2026.
  10. PubMed indexed literature. Cardiolipin and electron transport chain review literature. PubMed database. Accessed 2026.
  11. MedlinePlus Genetics. Barth syndrome. U.S. National Library of Medicine. Accessed 2026.
  12. PubMed indexed literature. Karaa and colleagues: elamipretide in primary mitochondrial myopathy. PubMed database / Neurology literature. 2018.
  13. U.S. National Library of Medicine. Clinical trial record: NCT03323749. ClinicalTrials.gov. Accessed 2026.
  14. U.S. National Library of Medicine. ClinicalTrials.gov search: elamipretide and Barth syndrome. ClinicalTrials.gov database. Accessed 2026.
  15. U.S. National Library of Medicine. ClinicalTrials.gov search: elamipretide and heart failure. ClinicalTrials.gov database. Accessed 2026.
  16. PubMed indexed literature. Elamipretide/Bendavia and reperfusion injury research. PubMed database. Accessed 2026.
  17. PubMed indexed literature. SS-31 kidney ischemia and mitochondrial research. PubMed database. Accessed 2026.
  18. MedlinePlus. Mitochondrial diseases. U.S. National Library of Medicine. Accessed 2026.
  19. DailyMed. Elamipretide labeling search. U.S. National Library of Medicine. Accessed 2026.
  20. National Center for Biotechnology Information. Clinical trial design and evidence interpretation overview. NCBI Bookshelf. Accessed 2026.
  21. U.S. Food and Drug Administration. Development and Approval Process for Drugs. FDA. Accessed 2026.

Contributing Authors

The following authors are recognized for published research that helped shape the scientific and clinical context discussed in this article.

Hazel H. Szeto

Author profile: PubMed Author Profile

Hazel H. Szeto’s publications are central to the published literature on Szeto-Schiller peptides, including SS-31 and related mitochondria-targeted tetrapeptides. Her work is relevant to understanding the mechanism of action discussed in this article, especially inner mitochondrial membrane targeting, cardiolipin-associated mitochondrial biology, oxidative injury models, and the distinction between preclinical research and clinical evidence. These publications provide useful scientific context for interpreting SS-31 peptide research without extending model-specific findings into unsupported therapeutic claims.

Selected publications:

Peter W. Schiller

Author profile: PubMed Author Profile

Peter W. Schiller’s peptide chemistry and pharmacology publications are relevant to the broader Szeto-Schiller peptide research lane. His coauthored work helps frame how mitochondria-targeted peptides were investigated in experimental systems involving mitochondrial swelling, oxidative cell injury, reperfusion injury, and membrane-focused peptide design. This research is most useful as mechanistic and preclinical context, supporting careful interpretation of SS-31-related findings rather than broad claims about clinical use.

Selected publications: